SGO Annual Meeting | Conference

Mirvetuximab Soravtansine/Rucaparib Shows Early Tolerability, Activity in Ovarian and Endometrial Cancers

March 29th 2021

The combination of mirvetuximab soravtansine and rucaparib was found to be well tolerated, with encouraging activity reported in heavily pretreated patients with endometrial, ovarian, fallopian tube, or primary peritoneal cancer.

Farletuzumab/Chemo Fails to Improve PFS in Platinum-Sensitive, Recurrent Ovarian Cancer With Low CA-125

March 25th 2021

The addition of farletuzumab to carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin did not demonstrate superiority over placebo plus chemotherapy in patients with platinum-sensitive recurrent ovarian cancer who are in their first relapse and have low cancer antigen-125 levels.

Mirvetuximab Soravtansine Monotherapy Under Exploration in Platinum-Resistant FRα+ Ovarian Cancer

March 25th 2021

The exploration of mirvetuximab soravtansine as a potentially efficacious treatment in patients with advanced, high-grade, platinum-resistant epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor–alpha expression continues with the ongoing, single-arm, phase 3 SORAYA trial.

Dostarlimab Delivers Durable Responses in dMMR/MMRp Endometrial Cancer

March 24th 2021

Dostarlimab demonstrated durable antitumor activity in patients with mismatch repair deficient and MMR proficient endometrial cancer, regardless of investigator assessment or blinded independent central review and immune-related RECIST or RECIST v1.1 criteria.

AVB-500/Paclitaxel Demonstrates Clinical Benefit in Platinum-Resistant Ovarian Cancer

March 23rd 2021

The GAS6/AXL inhibitor AVB-500, when combined with paclitaxel, elicited clinical benefit with favorable tolerability in patients with platinum-resistant ovarian cancer, according to data from a phase 1b study.

Olaparib Maintains Acceptable Safety Profile in Platinum-Sensitive, Relapsed Ovarian Cancer

March 22nd 2021

Olaparib, when used in patients with platinum-sensitive relapsed ovarian cancer who had a known BRCA mutation and homologous recombination deficiency status, demonstrated adverse effects that proved to be consistent with the established safety profile of the PARP inhibitor.

Olaparib/Cediranib Fails to Significantly Improve PFS Over Cediranib Alone in Advanced Endometrial Cancer

March 22nd 2021

Although the combination of olaparib and cediranib showcased modest efficacy over cediranib alone in patients with recurrent, metastatic or persistent endometrial cancer, the difference was not statistically significant.

Pembrolizumab/Lenvatinib Improves Survival, ORR in Advanced Endometrial Cancer, Regardless of MMR Status

March 20th 2021

The combination of pembrolizumab and lenvatinib improved progression-free and overall survival, as well as response rates, compared with chemotherapy in patients with advanced endometrial cancer who received prior platinum-based chemotherapy, irrespective of mismatch repair status, according to phase 3 findings of the Study-309/KEYNOTE-775 trial.

Analyses Underscore Extent of Frontline Maintenance Niraparib Benefit in Ovarian Cancer

April 11th 2020

The success of frontline maintenance niraparib in the phase III PRIMA trial extends to meeting biomarker-defined and other secondary endpoints and showing positive patient-reported outcomes.

Addition of Trastuzumab to Chemo Boosts Survival in HER2+ Uterine Serous Carcinoma

April 10th 2020

The addition of trastuzumab to carboplatin and paclitaxel resulted in a significant survival benefit in women with advanced or recurrent, HER2-positive uterine serous carcinoma, with the greatest benefit observed in those with stage III/IV disease who received the regimen up front.

Dr. O'Malley on Increased Benefit of Rucaparib Maintenance in RAD51C/D-Mutant Ovarian Cancer

April 10th 2020

David O'Malley, MD, discusses the increased benefit of rucaparib maintenance in patients with ovarian cancer who express RAD51C/D mutations.

Dr. Swisher on the Implications of the VELIA Trial in Ovarian Cancer

April 10th 2020

Elizabeth M. Swisher, MD, discusses the implications of the phase III VELIA/GOG-3005 trial in ovarian cancer.

Dr. O'Malley on Maintenance Rucaparib in Non-BRCA HRR-Mutated Ovarian Cancer

April 9th 2020

David O’Malley, MD, discusses the rationale to evaluate the clinical benefit of rucaparib maintenance treatment following disease progression in a subgroup of patients with ovarian cancer whose disease is associated with a mutation in a non-BRCA homologous recombination gene in the phase III ARIEL3 trial in ovarian cancer.

Dr. Fader on Adding Trastuzumab to Chemo in HER2+ Uterine Serous Carcinoma

April 9th 2020

Amanda Nickles Fader, MD, discusses findings from a randomized phase II trial examining the efficacy of adding trastuzumab to carboplatin/paclitaxel in patients with advanced or recurrent uterine serous carcinomas that overexpress HER2/neu.

Olaparib/Bevacizumab as Frontline Maintenance Improves PFS in Ovarian Cancer, Regardless of Timing of Surgery, Disease Status

April 8th 2020

The combination of olaparib and bevacizumab was found to improve progression-free survival outcomes versus bevacizumab alone as a frontline maintenance treatment in patients with newly diagnosed advanced high-grade serous ovarian cancer, regardless of the timing of surgery or residual disease status after surgery.

Niraparib/Bevacizumab Combo as Frontline Maintenance Shows Promise in Advanced Ovarian Cancer

April 8th 2020

The combination of niraparib and bevacizumab as a frontline maintenance therapy was found to have impressive clinical activity in patients with advanced ovarian cancer who had a complete or partial response to frontline platinum-based chemotherapy plus bevacizumab.

Trametinib Boosts PFS and Response Rates in Low-Grade Ovarian Cancer

April 7th 2020

Trametinib monotherapy has emerged as a new treatment option for women with recurrent low-grade serous ovarian cancers based on improvements in survival outcomes and response rates demonstrated in a phase II/III study.

Analysis Pinpoints Veliparib Antitumor Activity in Ovarian Cancer

April 6th 2020

Adding veliparib to frontline induction chemotherapy increased complete and CA-125 responses compared with chemotherapy alone in patients with high-grade serous ovarian cancer, according to an exploratory analysis of the phase III VELIA trial.

Dr. Chase on Niraparib as Frontline Maintenance Therapy in Ovarian Cancer

April 4th 2020

Dana Chase, MD, discusses niraparib as frontline maintenance therapy in ovarian cancer.

Rucaparib Improves Postprogression Outcomes in Non-BRCA HRR Mutated Ovarian Cancer

April 3rd 2020

Rucaparib was associated with superior outcomes among women with ovarian cancer harboring a non-BRCA homologous recombination repair gene mutation compared with placebo, according to an analysis of specimens collected in the phase III ARIEL3 trial (NCT01968213).